COMMUNIQUÉS West-GlobeNewswire
-
Genesis HealthCare Sells 51% Stake in Chinese Subsidiary GRS-HS to Riswein Health Industry Investment Co., Ltd
23/04/2018 - 22:05 -
Harvard Bioscience Schedules First Quarter 2018 Conference Call for May 2 at 4:30 PM ET
23/04/2018 - 22:05 -
ChromaDex Appoints Frank Jaksch As Executive Chairman, Rob Fried as Chief Executive Officer and Kurt Gustafson as Lead Director
23/04/2018 - 22:05 -
Tivity Health Reports First-Quarter 2018 Results and Affirms Financial Guidance
23/04/2018 - 22:05 -
Avadim Technologies Receives Notices of Allowance From U.S. and Japan Patent Offices for Inventions Related to Reducing Catheter Associated Urinary Tract Infections (CAUTI)
23/04/2018 - 22:02 -
Adventist Health and St. Joseph Health Announce Formation of a New Joint Operating Company
23/04/2018 - 22:02 -
Optinose CEO Peter Miller and President/COO Ramy Mahmoud Named EY Entrepreneur of the Year 2018 Finalists in the Greater Philadelphia Area
23/04/2018 - 22:01 -
Nuvectra™ to Report First Quarter 2018 Financial Results on May 2, 2018
23/04/2018 - 22:01 -
Nohla Therapeutics Announces Hiring of Gary Christianson as Chief Operating Officer
23/04/2018 - 22:00 -
Probiodrug Appoints Dr. Ulrich Dauer as Chief Executive Officer
23/04/2018 - 20:46 -
Samumed’s Osteoarthritis and Tendinopathy Research Selected for Multiple Presentations at the 2018 Osteoarthritis Research Society International (OARSI) World Congress
23/04/2018 - 20:00 -
Title21 Health Solutions Honored as a ‘Best Place to Work’ for the Second Year in a Row
23/04/2018 - 18:15 -
Summit Therapeutics plc : Director/PDMR Shareholding
23/04/2018 - 18:06 -
Ossur Hf : Transactions in relation to share buyback program
23/04/2018 - 18:01 -
OSE Immunotherapeutics Receives the EuroNext Tech40 Label
23/04/2018 - 18:00 -
Diaxonhit, acteur incontournable du diagnostic in vitro et des sciences de la vie: Résultats annuels 2017
23/04/2018 - 17:46 -
Shire plc : Holding(s) in Company
23/04/2018 - 17:46 -
Emblem Announces Investment in Fire & Flower
23/04/2018 - 17:33 -
Pernix Therapeutics Announces Participation in Lead Bid for Acquisition of Worldwide Rights to Contrave® for Weight Loss
23/04/2018 - 17:30
Pages